Applicatio	110111111111111111111111111111111111111	ΓRANSMI	TTAL LE	<u></u>	Docket No. 1422-0619
Application No.		Filing Date		Examiner	Art
10/743,740-Conf. #9686		December	24, 2003	K. Habte	16
pplicant(s): Eiicl	hi IISHI et al.				
nvention: ANHYE	OROUS MIRTA	AZAPINE CRY	STALS AND	PROCESS FOR PRE	PARING THE
MS RCE Commissioner for I P.O. Box 1450 Alexandria, VA 223 Transmitted here	313-1450	ndment in the	above-identif	ied application.	
The fee has been	n calculated an	d is transmitte	d as shown b	elow.	
	CLAIMS AS AMENDED				
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	5	- 20 =	0	х	
Independent Claims	3	- 3 =	0	x	
Multiple Depend	lent Claims (ch	eck if applicabl	le)		
Other fee (please specify): Request for continued examination (RCE)					790.0
TOTAL ADDIT	IONAL FEE FO	OR THIS AME	NDMENT:		790.0
x Large Entity				Small Entity	
No additiona	al fee is require	d for this amer	ndment.		
Please charg	ge Deposit Acc	count No	ir	n the amount of \$	
	copy of this she				
X A check in th	ne amount of \$	790.00	to cover	the filing fee is enclos	sed.
Payment by	credit card. Fo	orm PTO-2038	is attached.		
	•	norized to chargolicate copy of	•	Deposit Account No. enclosed.	02-2448
as described	ny overpaymer	nt.			
as described	ny overpaymer		on processing t	fees required under 37	CFR 1.16 and 1
as described	ny overpaymer	ing or applicatio	on processing t	·	
as described	ny overpaymer any additional fili ohy, Jr.		on processing t	·	CFR 1.16 and 1 anuary 3, 2006



Docket No.: 1422-0619P

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Eiichi IISHI et al.

Application No.: 10/743,740

Confirmation No.: 9686

Filed: December 24, 2003

Art Unit: 1624

For: ANHYDROUS MIRTAZAPINE CRYSTALS

Examiner: K. Habte

AND PROCESS FOR PREPARING THE SAME

<u>AMENDMENT UNDER 37 C.F.R. § 1.111 AND 1.114</u>

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INTRODUCTORY COMMENTS

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.